Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, December 9, 2015

People with Relapsing NMOD Invited to Enter Phase 3 Study

<span class="entry-title">People with Relapsing NMOD Invited to Enter Phase 3 Study</span><span class="entry-subtitle">Trial to evaluate eculizumab as possible neuromyelitis optica spectrum disorder treatment</span>

Trial to evaluate eculizumab as possible neuromyelitis optica spectrum disorder treatment

The National Multiple Sclerosis Society recently announced that a research team is now recruiting 132 patients with a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) for a Phase 3 clinical study comparing an experimental medicine with an inactive placebo.
NMOSD is a rare disorder caused by immune system cells attacking healthy cells; these attacks are directed mostly against the eyes and spinal cord. NMOSD is considered a distinct disease from multiple sclerosis (MS), although both are inflammatory diseases of the central nervous system and sometimes difficult to distinguish between. NMOSD causes inflammation of the spinal cord and optic nerve, which can lead to the loss of vision, mobility, and sensation. The condition currently has no cure or approved drugs, and investigators are seeking a treatment to prevent attacks or relapses.
Ninety percent of NMOSD patients have a relapsing form of the disease, and many continue to experience attacks despite disease management. Disability can worsen with every relapse.
The new study, called PREVENT, is sponsored by Alexion Pharmaceuticals, Inc., and will evaluate the efficacy and safety of the investigational drug eculizumab for the treatment of patients with relapsing NMOSD.

MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: